This Albuminex market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to factors such as the rising prevalence of chronic diseases, an increase in the number of surgeries, the expanding aging population, higher healthcare expenditure, and growth in government initiatives.
Market growth during the forecast period is expected to be driven by factors such as rising investments in research and development, the growing prevalence of hypoalbuminemia, a higher incidence of autoimmune diseases, an increasing number of life-threatening illnesses, and a greater number of plasma collection centers. Key trends during this period include advancements in technology, improvements in purification technologies, the rise of personalized medicine, developments in regenerative medicine, and the application of nanotechnology.
The growing incidence of liver cancer is expected to drive the expansion of the albuminex market. Liver cancer occurs when abnormal liver cell growth, often due to chronic conditions or lifestyle factors, results in malignant tumors in the liver. The rising number of liver cancer cases can be attributed to risk factors such as chronic hepatitis, obesity, alcohol consumption, and an aging population. Albuminex is essential in the treatment of liver cancer to manage fluid imbalances and maintain oncotic pressure in patients with impaired liver function, helping to prevent complications such as ascites and edema. For example, in July 2024, Cancer Research UK predicted that new liver cancer cases would rise from approximately 7,600 annually between 2023-2025 to around 9,700 annually by 2038-2040. Liver cancer incidence rates are projected to increase by 6%, reaching 12 cases per 100,000 people per year by 2038-2040. This increase will affect both males and females, with a slightly higher rise in females (8%) compared to males (4%). By 2038-2040, the incidence rate for females is expected to reach 8 cases per 100,000 annually, while for males, it will be 16 cases per 100,000 per year. Consequently, the rising incidence of liver cancer is driving the growth of the albuminex market.
The growth in pharmaceutical and medicinal research activities is also expected to contribute to the expansion of the albuminex market. Pharmaceutical and medicinal research involves the systematic development of new drugs, treatments, and therapies to improve healthcare and disease management. These activities are increasing due to advancements in technology, rising healthcare needs, and a focus on innovative therapies for complex and rare diseases. Pharmaceutical and medicinal research activities positively impact Albuminex by driving the development of advanced albumin-based therapies, improving manufacturing processes, broadening clinical applications (such as drug delivery systems and critical care), and fostering innovations that enhance product efficacy, safety, and market adoption. For instance, in July 2024, the Department of Health and Social Care reported that the business enterprise sector in the UK conducted $11.4 billion (£9 billion) in pharmaceutical research and development in 2022, accounting for 0.36% of the country's GDP. Pharmaceutical R&D represented 18% of all research and development activities conducted by businesses in the UK, making it the leading area of investment. As a result, the growth in pharmaceutical and medicinal research activities is fueling the growth of the albuminex market.
A significant trend in the albuminex market is the innovation of human albumin solutions, aimed at meeting the increasing demand for effective treatments in critical care. Human albumin solutions are sterile preparations derived from human plasma, used to restore blood volume and treat hypoalbuminemia. For example, in January 2022, Bio Products Laboratory, a UK-based manufacturer of plasma-derived medicines, received approval from the National Medical Products Administration (NMPA) to market its ALBUMINEX 25% product in China. This product, indicated for conditions such as hypovolemia, ascites, and hypoalbuminemia, is produced from human plasma using a rigorous four-step purification process, achieving over 99% purity. Ready-to-use, the product simplifies administration in clinical settings without preparation, ensuring accuracy and reliability for patient care. With a shelf life of 24 months due to a proprietary preservation formula, this launch enhances quality assurance in albumin-related treatments across healthcare facilities.
The key company operating in the albuminex market is Bio Products Laboratory Limited.
North America was the largest region in the albuminex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albuminex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuminex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Albuminex is a specific formulation of human albumin, a protein found in blood plasma. Albumin plays a key role in maintaining the osmotic pressure of blood, which helps regulate fluid balance in the body. It is commonly used in medical treatments for conditions such as burns, shock, liver disease, and kidney problems, where blood volume and protein levels are critically low.
The main types of albuminex include human serum albumin, bovine serum albumin, and recombinant human serum albumin. Human serum albumin, derived from human plasma, is essential for maintaining blood volume and osmotic pressure. It is used for a variety of clinical indications, including hypovolemia, hypoalbuminemia, oncotic pressure regulation, cardiopulmonary bypass surgery, acute respiratory distress syndrome (ARDS), therapeutic plasma exchange (TPE), burn management, sepsis and septic shock, among others. Albuminex is distributed through several channels, such as hospital pharmacies, retail and specialty pharmacies, and online platforms. It is used by hospitals, clinics, pharmaceutical and biotechnology industries, and research institutes.
The albuminex market research report is one of a series of new reports that provides albuminex market statistics, including albuminex industry global market size, regional shares, competitors with a albuminex market share, detailed albuminex market segments, market trends and opportunities, and any further data you may need to thrive in the albuminex industry. This albuminex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The albuminex market consists of sales of albumin concentrates, albumin-based drug delivery systems, albumin-based vaccines and recombinant albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to factors such as the rising prevalence of chronic diseases, an increase in the number of surgeries, the expanding aging population, higher healthcare expenditure, and growth in government initiatives.
Market growth during the forecast period is expected to be driven by factors such as rising investments in research and development, the growing prevalence of hypoalbuminemia, a higher incidence of autoimmune diseases, an increasing number of life-threatening illnesses, and a greater number of plasma collection centers. Key trends during this period include advancements in technology, improvements in purification technologies, the rise of personalized medicine, developments in regenerative medicine, and the application of nanotechnology.
The growing incidence of liver cancer is expected to drive the expansion of the albuminex market. Liver cancer occurs when abnormal liver cell growth, often due to chronic conditions or lifestyle factors, results in malignant tumors in the liver. The rising number of liver cancer cases can be attributed to risk factors such as chronic hepatitis, obesity, alcohol consumption, and an aging population. Albuminex is essential in the treatment of liver cancer to manage fluid imbalances and maintain oncotic pressure in patients with impaired liver function, helping to prevent complications such as ascites and edema. For example, in July 2024, Cancer Research UK predicted that new liver cancer cases would rise from approximately 7,600 annually between 2023-2025 to around 9,700 annually by 2038-2040. Liver cancer incidence rates are projected to increase by 6%, reaching 12 cases per 100,000 people per year by 2038-2040. This increase will affect both males and females, with a slightly higher rise in females (8%) compared to males (4%). By 2038-2040, the incidence rate for females is expected to reach 8 cases per 100,000 annually, while for males, it will be 16 cases per 100,000 per year. Consequently, the rising incidence of liver cancer is driving the growth of the albuminex market.
The growth in pharmaceutical and medicinal research activities is also expected to contribute to the expansion of the albuminex market. Pharmaceutical and medicinal research involves the systematic development of new drugs, treatments, and therapies to improve healthcare and disease management. These activities are increasing due to advancements in technology, rising healthcare needs, and a focus on innovative therapies for complex and rare diseases. Pharmaceutical and medicinal research activities positively impact Albuminex by driving the development of advanced albumin-based therapies, improving manufacturing processes, broadening clinical applications (such as drug delivery systems and critical care), and fostering innovations that enhance product efficacy, safety, and market adoption. For instance, in July 2024, the Department of Health and Social Care reported that the business enterprise sector in the UK conducted $11.4 billion (£9 billion) in pharmaceutical research and development in 2022, accounting for 0.36% of the country's GDP. Pharmaceutical R&D represented 18% of all research and development activities conducted by businesses in the UK, making it the leading area of investment. As a result, the growth in pharmaceutical and medicinal research activities is fueling the growth of the albuminex market.
A significant trend in the albuminex market is the innovation of human albumin solutions, aimed at meeting the increasing demand for effective treatments in critical care. Human albumin solutions are sterile preparations derived from human plasma, used to restore blood volume and treat hypoalbuminemia. For example, in January 2022, Bio Products Laboratory, a UK-based manufacturer of plasma-derived medicines, received approval from the National Medical Products Administration (NMPA) to market its ALBUMINEX 25% product in China. This product, indicated for conditions such as hypovolemia, ascites, and hypoalbuminemia, is produced from human plasma using a rigorous four-step purification process, achieving over 99% purity. Ready-to-use, the product simplifies administration in clinical settings without preparation, ensuring accuracy and reliability for patient care. With a shelf life of 24 months due to a proprietary preservation formula, this launch enhances quality assurance in albumin-related treatments across healthcare facilities.
The key company operating in the albuminex market is Bio Products Laboratory Limited.
North America was the largest region in the albuminex market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in albuminex report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the albuminex market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Albuminex is a specific formulation of human albumin, a protein found in blood plasma. Albumin plays a key role in maintaining the osmotic pressure of blood, which helps regulate fluid balance in the body. It is commonly used in medical treatments for conditions such as burns, shock, liver disease, and kidney problems, where blood volume and protein levels are critically low.
The main types of albuminex include human serum albumin, bovine serum albumin, and recombinant human serum albumin. Human serum albumin, derived from human plasma, is essential for maintaining blood volume and osmotic pressure. It is used for a variety of clinical indications, including hypovolemia, hypoalbuminemia, oncotic pressure regulation, cardiopulmonary bypass surgery, acute respiratory distress syndrome (ARDS), therapeutic plasma exchange (TPE), burn management, sepsis and septic shock, among others. Albuminex is distributed through several channels, such as hospital pharmacies, retail and specialty pharmacies, and online platforms. It is used by hospitals, clinics, pharmaceutical and biotechnology industries, and research institutes.
The albuminex market research report is one of a series of new reports that provides albuminex market statistics, including albuminex industry global market size, regional shares, competitors with a albuminex market share, detailed albuminex market segments, market trends and opportunities, and any further data you may need to thrive in the albuminex industry. This albuminex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The albuminex market consists of sales of albumin concentrates, albumin-based drug delivery systems, albumin-based vaccines and recombinant albumin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Albuminex Market Characteristics4. Albuminex Market Trends and Strategies5. Albuminex Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Albuminex Pricing Analysis & Forecasts30. Global Albuminex Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Albuminex Market32. Recent Developments in the Albuminex Market
3. Albuminex Market Biologic Drug Characteristics
6. Global Albuminex Growth Analysis and Strategic Analysis Framework
8. Albuminex Market Segmentation
9. Global Albuminex Epidemiology of Clinical Indications
10. Albuminex Market Regional and Country Analysis
11. Asia-Pacific Albuminex Market
12. China Albuminex Market
13. India Albuminex Market
14. Japan Albuminex Market
15. Australia Albuminex Market
16. South Korea Albuminex Market
17. Western Europe Albuminex Market
18. UK Albuminex Market
19. Germany Albuminex Market
20. France Albuminex Market
21. Eastern Europe Albuminex Market
22. North America Albuminex Market
23. USA Albuminex Market
24. Canada Albuminex Market
25. South America Albuminex Market
26. Middle East Albuminex Market
27. Africa Albuminex Market
28. Albuminex Market Competitive Landscape and Company Profiles
29. Global Albuminex Market Pipeline Analysis
33. Albuminex Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Albuminex Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on albuminex market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for albuminex? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The albuminex market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Type: Human Serum Albumin; Bovine Serum Albumin; Recombinant Human Serum Albumin2) by Clinical Indication: Hypovolemia; Hypoalbuminemia; Oncotic Pressure Regulation; Cardiopulmonary Bypass Surgery; Acute Respiratory Distress Syndrome (ARDS); Therapeutic Plasma Exchange (TPE); Burn Management; Sepsis and Septic Shock; Other Clinical Indications
3) by Distribution Channel: Hospital Pharmacies; Retail and Specialty Pharmacies; Online Pharmacies
4) by End User: Hospital and Clinics; Pharmaceutical and Biotechnology Industry; Research Institutes
Key Companies Mentioned: Bio Products Laboratory Limited
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Bio Products Laboratory Limited
